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Plasmodium vivax is a human malaria parasite responsible for signiﬁcant morbidity
worldwide and potentially death. This parasite possesses formidable liver-stage biology
that involves the formation of dormant parasites known as hypnozoites. Hypnozoites
are capable of activating weeks, months, or years after a primary blood-stage infection
causing relapsing bouts of illness. Elimination of this dormant parasitic reservoir will be
critical for global malaria eradication. Although hypnozoites were ﬁrst discovered in 1982,
few advancements have been made to understand their composition and biology. Until
recently, in vitro models did not exist to study these forms and studying them from human
ex vivo samples was virtually impossible. Today, non-human primate (NHP) models and
modern systems biology approaches are poised as tools to enable the in-depth study
of P. vivax liver-stage biology, including hypnozoites and relapses. NHP liver-stage model
systems forP. vivax and the related simianmalaria speciesP. cynomolgi are discussed along
with perspectives regarding metabolite biomarker discovery, putative roles of extracellular
vesicles, and relapse immunobiology.
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Malaria is responsible for signiﬁcant morbidity, mortality, and
socioeconomic hardships in about 100 countries (World Health
Organization, 2014). The causative agents of the disease are
parasitic protists of the genus Plasmodium, which have a com-
plex life-cycle involving a vertebrate and invertebrate host. After
infecting susceptible mammals, the parasite undergoes obligate,
clinically silent development in the liver prior to entering the
blood and causing the clinical symptoms and pathology associ-
ated with malaria. Neutralizing the parasites in the liver has been
a goal to prevent blood-stage infection and, therefore, clinical dis-
ease and transmission. Indeed, targeting liver stage forms (LSFs)
has been a strong theme in current anti-malarial drug and vaccine
efforts (Abdulla et al., 2011; Duffy et al., 2012). Moreover, prevent-
ing relapse infections is especially important in light of research
demonstrating that the majority of Plasmodium vivax malaria
episodes are due to relapses, which result from the activation of
dormant forms in the liver, and not from new, mosquito-borne
infections (Betuela et al., 2012; White et al., 2014).
Naturally, human clinical studies relating to the biology of LSFs
and host–pathogen interactions in the liver are prohibitive, and
regardless, inﬂuenced by uncontrollable variables; e.g., diet and
medications. Unlikehuman studies, experimentalNHPmodel sys-
tems are well suited for studying LSFs and relapse biology. Future
malaria research with non-human primates (NHPs) on these top-
ics will undoubtedly include large-scale ‘omics,’ advanced immune
proﬁling,mathematical modeling, computational biology, and the
integration of clinical and ‘omics’ datasets (Galinski et al., 2013,
2014; Voit, 2013).
While research using NHPs will inevitably remain limited
worldwide within a few capable biomedical research centers, such
investigations with the public release of datasets will enable many
more investigators to participate in associated areas of research and
development. Moreover, collaborations with investigators at these
centers can lead to new research directions including much needed
translational studies to improve diagnostics and clinical care and
to develop and test new anti-malarial interventions and vaccine
candidates. From our perspective, these factors make NHP model
systems critical to advancing theworld towardmalaria eradication.
NHP-MALARIA MODELS OVERVIEW
Non-human primate model systems have been instrumental
in malaria research for decades whether for furthering basic
understanding of Plasmodium biology, malaria pathogenesis, or
preclinical investigations pertinent to developing new interven-
tions (Coatney et al., 1971; Collins, 1974; Galinski and Barnwell,
2012; Beignon et al., 2014). Notably, they were critical for the
discovery of dormant forms of the parasite in the liver, known as
hypnozoites. These formswere ﬁrst discovered in rhesusmacaques
(Macaca mulatta) experimentally infected with P. cynomolgi (Kro-
toski et al., 1982b), and then in chimpanzees infected with P. vivax
(Krotoski et al., 1982a). Research from the ﬁeld has conﬁrmed
that hypnozoites can stay dormant for weeks, months, or years
after a primary infection and then activate and result in relapses,
with new cycles of blood-stage parasitemias and illness (White
and Imwong, 2012). Recently, NHPs were critical for the devel-
opment of an in vitro, primary hepatocyte culture system that
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supported the cultivation of P. cynomolgi LSFs for approximately
40 days and provided the ﬁrst tangible evidence that hypnozoites
existed and were capable of activating and multiplying to gen-
erate merozoites (Barnwell and Galinski, 2014; Dembele et al.,
2014).
Various NHP-simian and human malaria parasite combina-
tions can be used to study Plasmodium biology. Many strains of
the parasites that infect NHPs, including four validated relaps-
ing species, are available and can be used to address scientiﬁc
questions relating to LSF biology (Table 1). Different strains of P.
cynomolgi and P. vivax that possess distinctive relapse patterns can
be utilized to study the consequences of frequent versus infrequent
relapses on the host immune system.A suitablemousemodel is not
currently available to study such phenomena. Indeed, humanized
mice containing human hepatocytes have been demonstrated to
support P. falciparum liver-stage growth (Vaughan et al., 2012;
Kaushansky et al., 2014). These models also appear to have some
utility for P. vivax because they appear to support the development
of hypnozoites (Mikolajczak et al., 2013). However, thesemice lack
intact immune systems and, thus, are deﬁcient when addressing
immunobiological questions, whether for P. falciparum or other
primate malaria species (Kaushansky et al., 2014).
VIVAX MALARIA – NHP MODELS
While NHP models have been used occasionally to supplement
fundamental P. falciparum research ﬁndings from culture systems
and for pre-clinical studies, P. vivax research over the last few
decades would have been virtually impossible without NHP mod-
els; i.e.,Aotus and Saimiri monkeys (Galinski and Barnwell, 2012).
Unlike P. falciparum, a long-term in vitro culture system for P.
vivax does not currently exist due to the need for a regular supply
of reticulocytes (Noulin et al., 2013), and thus, we believe yet to be
deﬁned culturemedia components that bettermimic thehost envi-
ronment are also needed (unpublished data). In the meantime,
NHP models have been critical for generating P. vivax material for
in-depth analyses (Anderson et al., 2015) and NHP experimental
studies continue to complement and expand upon blood-stage
analyses that are now possible with small clinical samples attained
from human infections (Russell et al., 2012; Galinski et al., 2014).
To investigate hypnozoites and relapses, Aotus orSaimiri species
can be infected with NHP-adapted P. vivax strains via mosquito
inoculation or syringe injection of sporozoites into a blood ves-
sel (Table 1; Galinski and Barnwell, 2012; Galinski et al., 2013).
Similar to human infections, relapsing, recrudescing, or chronic
infection proﬁles can be observed in these models provided the
animals are splenectomized to interfere with an overly robust
removal of infected erythrocytes (Figure 1). In contrast to relapses,
recrudescences are the result of untreated or persistent blood-stage
infections that become sub-patent, below the level of detection
by microscopy, followed by an eventual return to patency; such
recurring parasitemias are distinct from relapse parasitemias that
are due to the activation of hypnozoites and release of a new brood
of merozoites from the liver.
Blood-stage parasitemias, which begin to develop within
8–10 days, can be curatively treated without destroying the
hypnozoites. PCR testing can conﬁrm the absence of blood-stage
parasites, and thus, any subsequent blood-stage infections can be
conﬁrmed as relapses and not recrudescences. This experimental
strategy is currently the only reliable means to study vivax relapses,
with the caveats that these animals are small (typically about 1 kg),
parasitemia is typically low or moderate (1–2%), and only small
blood volumes can be taken (6 ml/kg/month) based on Institu-
tional Animal Care and Use Committee (IACUC) guidelines. One
strain in particular (named the Brazil VII strain) is being devel-
oped at the Centers for Disease Control and Prevention (CDC)
for studying relapses as it shows multiple relapse patterns over a
period of several months similar to that observed previously in
humans with “tropical strains” (Table 1).
SIMIAN PARASITE – NHP MODELS FOR VIVAX MALARIA
Simian malaria parasite-NHP models are powerful systems to
investigate LSF biology, hypnozoites, and relapses compared to
the small New World NHPs. Simian malaria parasites produc-
tively infect Old World monkeys, including rhesus macaques
(M. mulatta) and long-tailed macaques (M. fascicularis), which
possess similar genetic composition and physiology to humans
(Gardner and Luciw, 2008; Messaoudi et al., 2011; Zimin et al.,
2014). The macaques are much larger than New World mon-
keys, which allows for greater blood or bone marrow draws
(up to a maximum of 10 ml/kg/month) for isolation of parasite
material and host cells for immunobiological studies. Addition-
ally, more reagents exist for experimentation with these NHP
species. Furthermore, large amounts of liver-material can be col-
lected via biopsies or whole livers to isolate LSFs for downstream
experiments.
Plasmodium cynomolgi is a “sister species” of P. vivax. These
closely related parasites share similar biology such as the forma-
tion of hypnozoites and caveolae vesicle complexes in infected
erythrocytes (Aikawa et al., 1975; Akinyi et al., 2012; Tachibana
et al., 2012). Tens of millions of P. cynomolgi sporozoites can be
generated in a speciﬁed, experimental time-frame compared to
P. vivax sporozoites which are more difﬁcult to generate (Rosen-
berg and Rungsiwongse, 1991; unpublished data). They can then
be used to experimentally infect macaques and lead to produc-
tive blood-stage parasitemias (Collins et al., 1999). Furthermore,
the same experimental approach used in Small New World Mon-
key infections with P. vivax can be employed to study relapses
(see Vivax Malaria – NHP Models). Two other simian malaria
species that could be useful for studying hypnozoites or relapse
mechanisms are P. ﬁeldi and, especially, P. simiovale (Table 1).
As with P. vivax, many P. cynomolgi isolates exist that have their
own infection and relapse characteristics (Table 1). The number
and frequency of relapses in rhesus infected with different strains
of P. cynomolgi can be predicted with greater accuracy than typ-
ically possible with New World monkey-adapted P. vivax isolates
although P. vivax Brazil VII has so far been uniquely dependable
in this regard (unpublished data). In rhesus, variables such as the
sporozoite inoculumcan be altered to produce consistent infection
patterns even though inter-individual variability between animals
as well as inherent properties of the strain being used in the study
can inﬂuence infection kinetics (Schmidt, 1986).
Plasmodium cynomolgi can be genetically manipulated more
easily than P. vivax, though P. vivax transfection has been
accomplished at the CDC and Emory, where transient transfection
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FIGURE 1 | Shared infection characteristics of human and simian malaria parasites.
of trophozoites was demonstrated in Saimiri boliviensis (Pfahler
et al., 2006). In recent years, we have developed P. cynomolgi
parasites with integrated transgenes, including a red ﬂuorescent
protein (rfp) gene (Akinyi et al., 2012; unpublished data). Tran-
sient RFP- and green ﬂuorescent protein-expressing P. cynomolgi
parasites have also been reported and used to purify P. cynomolgi
LSFs from NHP primary hepatocyte cultures using ﬂuorescence-
activated cell sorting (Voorberg-van derWel et al., 2013). Technical
hurdles such as achieving better yields of puriﬁed parasites for
downstreamexperiments still remain. Nonetheless, these aremon-
umental breakthroughs given the challenges working with these
parasites.
PRIMARY NHP HEPATOCYTE CULTURES
NHP primary hepatocyte cell cultures are valuable for exploratory
studies and may prove to be crucial for validating in vivo experi-
ments as well as mechanistic studies requiring gene knockdowns,
drug treatment, etc. Critical advancements have beenmade toward
optimizing in vitro studies with Plasmodium LSFs, particularly
with P. cynomolgi and rhesus monkey primary hepatocytes, even
though infection rates, and thus, parasite yields still remain low
(Voorberg-van der Wel et al., 2013). The most critical advance-
ment has been the establishment of a long-term culture system
using primary NHP hepatocytes that can support P. cynomolgi
hypnozoites and other LSFs for up to 40 days; importantly, this
system allows for hypnozoites to activate and develop into sch-
izonts capable of releasing merozoites (Barnwell and Galinski,
2014; Dembele et al., 2014). This breakthrough ramps up research
in this area and provides a workable system for validating in vivo
ﬁndings.
SYSTEMS BIOLOGY APPROACHES
Systems biology approaches have been recently pioneered to
study infectious diseases and vaccine efﬁcacy (Li et al., 2014;
Petrizzo et al., 2014; Zak et al., 2014). Systems biology foregoes
traditional reductionist approaches and focuses on a biological
system in its entirety. Typically, multiple ‘omics technologies are
employed to generate large datasets and methods are developed
to integrate those datasets. Advanced mathematics and statis-
tics are required to generate computational models of speciﬁc
biological processes, such as hematopoiesis, immune responses,
and infectious disease pathogenesis. Indeed, these strategies are
being utilized by the Malaria Host–Pathogen Interaction Center
(MaHPIC) using Old World and New World monkey mod-
els to study malaria and bring a wealth of data and novel
results to the research community via online resources. We
believe that systems biology approaches will likewise have util-
ity for studying Plasmodium LSFs and the mechanisms behind
relapses.
Systems biology methods can be attempted to study LSFs using
transgenic, ﬂuorescent LSFs isolated by ﬂuorescence-activated cell
sorting from ex vivo liver tissue. We and others (Voorberg-van
der Wel et al., 2013) hope to demonstrate that adequate, puri-
ﬁed ex vivo parasite material for downstream experimentation
can be attained using such strategies. Performing transcrip-
tomic, proteomic, and metabolomic analyses on the ex vivo
material holds potential for identifying biochemical and molec-
ular pathways important in hypnozoite biology. A hypnozoite
proteome may help elucidate new vaccine candidates whereas
transcriptome and metabolome data could give insight into other
potential biochemical and molecular pathways that could become
drug targets. Indeed, headway is being made in understanding
hypnozoite biology with the recent demonstration that epige-
netic programming could be responsible for latency (Dembele
et al., 2014). Notably, however, modifying epigenetic changes
in vivo may have detrimental side effects to the host organ-
ism, and thus, this may not be a feasible treatment strategy in
humans.
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We are well aware of the scientiﬁc and physiological chal-
lenges, but also optimistic that highly sensitive systems biol-
ogy approaches that include metabolomics can help identify
biomarkers that could predict the presence of hypnozoites and
serve as diagnostic tools. Metabolomics is a relatively new, yet
powerful, scientiﬁc discipline that is gaining traction in the ﬁght
against malaria (Olszewski et al., 2009; Kafsack and Llinás, 2010;
Lakshmanan et al., 2011; Salinas et al., 2014). It is exciting to con-
sider how high-resolution mass spectrometry could potentially
identify a metabolic biomarker(s) (predictably of host origin) in
the serum, plasma, urine, or saliva that is indicative of the presence
of LSFs and the need for treatment. Potential biomarkers are best
sought from an in vivo infection where host–parasite interactions
can be investigated in the context of the normal physiology of the
parasite and the host. Experimental NHP models can be infor-
mative in this regard. Diets and other variables can be controlled,
and infected samples can be collected daily, or even multiple times
daily if useful, over the course of a designated infection period
through multiple relapse episodes without the immediate, ethical
need for treatment.
EXTRACELLULAR VESICLES: POTENTIAL DIAGNOSTIC AND
THERAPEUTIC TARGETS
Extracellular vesicles (EVs) are a heterogeneous population of
small vesicles found in virtually all bodily ﬂuids including serum,
plasma, urine, saliva, etc., and are categorized into subtypes based
on their physical properties such as density, size, and shape as
well as their biogenesis (Kowal et al., 2014; Robbins and Morelli,
2014). These vesicles are produced by all multi- and unicellular
organisms examined to date, and different types of EVs contain
speciﬁc protein and RNA cargo dependent upon the cell-type the
EV originated from (Villarroya-Beltri et al., 2014).
The roles of liver-derived EVs on liver physiology have been
reviewed elsewhere (Imani Fooladi and Mahmoodzadeh Hosseini,
2014). Notably, multiple studies have implicated liver-derived EVs
in the life-cycle of liver pathogens. For example, exosomes, a
speciﬁc EV subtype that originates from a multivesicular body
within the cell, derived from liver non-parenchymal cells were
demonstrated to transfer resistance against hepatitis B virus infec-
tion to hepatocytes via an IFN-α mediated mechanism (Li et al.,
2013). Despite these implications of EVs in the liver, putative
roles of EVs have not been reported with regards to Plasmod-
ium liver-stage biology, but warrant attention. Indeed, EVs were
recently shown to be released from Plasmodium infected erythro-
cytes and implicated in a “density-dependent sensing mechanism”
that inﬂuences P. falciparum gametocytogenesis (Mantel et al.,
2013; Regev-Rudzki et al., 2013). These studies were the ﬁrst to
raise the possibility for a natural role of EVs during the life-cycle
and provide a ﬁrm rationale that such mechanisms may exist for
LSFs.
Extracellular vesicles could predictably serve as a commu-
nication mechanism between LSFs and inﬂuence hypnozoite
activation, and NHP, primary hepatocyte cultures can be used
to assess if such mechanisms exist. Cultures can be infected with
sporozoites, and EVs derived from uninfected and infected hepa-
tocytes can be isolated from the culture medium (Momen-Heravi
et al., 2013). The EVs can then be placed on LSF cultures harboring
different forms of the parasites, including hypnozoites, to directly
test if EVs isolated at different points of the LSF cycle (e.g., when
hypnozoites are activating) result in speciﬁc biological outcomes.
For example, one may predict that EVs isolated from cultures
with activated hypnozoites may signal other hypnozoites to exit
dormancy and multiply. These experiments are not perfect, how-
ever, and will be unable to delineate if the effect is caused by host
and/or parasite-derived EVs, but it is a starting point to explore
mechanisms and speciﬁc EV components that could potentially
be used to force hypnozoite activation.
If such a strategy of ‘waking up’ hypnozoites is feasible, akin to
the novel ideas suggested by others based on drug interventions
to target putative epigenetic control mechanisms of dormancy
(Dembele et al., 2014), only the blood-stages would have to be
treated, making treatment more straightforward with multiple
safe options compared to primaquine with its contraindications
(White et al., 2014). Indeed, as members of the MaHPIC, we have
been developing EV research strategies utilizing NHPs infected
with simian malaria parasites. EVs are challenging to purify, but
we have managed to purify them from small volumes of plasma,
observe them by electron microscopy, and conﬁrm their iden-
tity through other biochemical and physical means (unpublished
data).
Hepatocyte-derived EVs in the circulation could also com-
prise possible biomarkers of hypnozoites similar to biochemical
biomarkers identiﬁed by metabolomics (Deng et al., 2009; Vlassov
et al., 2012). Hepatocytes and other tissue-resident cells in the
liver release EVs that contain speciﬁc protein and RNA cargo that
become altered during liver injury (Farid et al., 2012). Similarly,
we hypothesize that the microRNA and protein content of liver-
derived EVs will be altered when hepatocytes are infected with
Plasmodium. If this proves to be the case, EVs could be potentially
isolated from serum, plasma, saliva, and/or urine and speciﬁc
diagnostic tests developed to use EVs as diagnostic markers of
hypnozoites. Although it may seem unlikely that EVs from Plas-
modium-infected hepatocytes could serve as biomarkers because
of the scarcity of infected hepatocytes (a relative few in an entire
liver), EVs are currently being explored to develop sensitive meth-
ods to detect cancer in bodily ﬂuids (Rak, 2013). If EV-based
diagnostic approaches are feasible andpromising for cancerswhere
few malignant cells exist, such approaches are worth exploring for
developing technologies to detect hypnozoites.
RELAPSE IMMUNOBIOLOGY
The immunobiology behind relapses, recrudescences, and chronic
infections (Figure 1) during malaria is poorly understood
although“immune exhaustion”during chronic infections has been
investigated recently (Wykes et al., 2014). This neglected area of
research needs attention because each of these distinctive infection
proﬁles could have unique effects on the host immune response;
e.g., to alter the host’s memory pool.
The team of immunologists at the MaHPIC has been using
NHP models to understand the effects of relapses on the host
immune system. Indeed, the consortium has determined that
relapses cause continuous expansion of the circulating memory B-
cell pool using theP. cynomolgi-rhesusmodel system (unpublished
data). Currently, the team is performing follow-up experiments to
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better understand this phenomenon and its immunological rele-
vance using sampling strategies that are not possible in humans.
Blood is being collected before, during, and after relapses to
monitor the alterations in the B-cell compartment by ﬂow cytom-
etry, with a special interest in memory B cells. The identities of
predominant B-cell clones based on immunoglobulin sequences
are being examined using Ig-Seq technologies (Georgiou et al.,
2014). The ﬁrst goal is to determine the clonal diversity of the
B-cell recall response against relapsing or challenge parasites.
The second goal is to assess which B-cell clones respond dur-
ing consecutive blood-stage infections. If consecutive blood-stage
infections are selecting for a particular subset of B-cells or, con-
trastingly, inducing proliferation of different B-cells, the host’s
memory B-cell pool could be signiﬁcantly altered. We predict that
alterations of the B-cell compartment could translate into poor
recall responses because memory B-cells, critical for detecting,
expanding, and producing antibodies to eliminate the parasites,
might be eliminated from the memory B-cell niche by other
B-cells that predominantly proliferate. If this proves to be the
case, the impact must be considered in light of developing a vac-
cine that relies on neutralizing antibodies mediated by memory
B-cells.
CONCLUSION
Non-human primate models of malaria have enabled major con-
tributions toward understanding liver-stage biology, hypnozoites,
and relapses, and will continue to provide the means to investigate
this enigmatic part of the Plasmodium life-cycle. Primaquine is
the only FDA-approved drug against hypnozoites despite its con-
traindications. Additionally, excessive use of this drug can support
the rise of primaquine resistant parasites (John et al., 2012; Price,
2014). A biomarker test would help restrict treatment to only
those individuals in need, and be useful in malaria elimination
campaigns where it is preferable to only treat infected individ-
uals instead of everyone to ensure elimination of the parasite
reservoir. New knowledge, techniques, and possible diagnostics,
vaccines, and medications that may result from studying LSFs
using NHP models will inevitably be key to malaria eradication
efforts.
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